The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Nuclear Transport In Health And Disease; Towards Therapeutics
Funder
National Health and Medical Research Council
Funding Amount
$851,980.00
Summary
This research fellowship will enable new therapeutic approaches to viral disease and cancer that target the transport process. I have already licenced an inhibitory molecule for Dengue virus which is progressing towards the clinic. I will now extend my research into a vibrant translational program of developing anti-viral (HIV, Respiratory Syncytical Virus, VEEV) as well as anti-cancer agents that will represent realistic therapeutic options in the near future.
Regulation Of Nucleocytoplasmic Transport; Role In Health And Disease
Funder
National Health and Medical Research Council
Funding Amount
$823,008.00
Summary
Transport into and out of the nucleus is central to the function of the cells from complex organisms such as mammals. This research program aims to improve understanding of nuclear transport and its regulation in the context of infection by medically relevant viruses, as well as in the context of cancer, and normal cell growth/development. It will contribute to developing new anti-viral therapeutics/vaccines, drug delivery strategies for cancer, and understanding causes of male infertility.
Halting The Spread Multidrug Resistant Uropathogenic E. Coli
Funder
National Health and Medical Research Council
Funding Amount
$687,975.00
Summary
Uropathogenic Escherichia coli (UPEC) is a major cause of urinary tract infection (UTI) and increasingly associated with resistance to multiple antibiotics. This project will study the virulence of multidrug resistant UPEC and use this knowledge to develop new approaches to treat and prevent UTI. The outcomes will be applicable to one of the most common infectious diseases of humans and have broad-reaching impact on our understanding of other infections caused by Gram-negative pathogens.
New Insights Into Viral Inflammatory Disease Mechanisms And Approaches To Therapy
Funder
National Health and Medical Research Council
Funding Amount
$631,010.00
Summary
This fellowship aims to establish how viruses cause disease, including how they evade the immune response to persist and cause disease for prolonged periods. My vision is that knowing how the virus and the immune system interact to determine disease severity will assist in devising new treatments and prevention programs to lessen the impact of viral diseases in Australia and worldwide.
Targeting Host Pathogen Interactions And Signalling Networks To Promote Death Of Infected Cells And Facilitate Pathogen Clearance
Funder
National Health and Medical Research Council
Summary
Preclinical models of infectious diseases including hepatitis B, HIV, tuberculosis and human herpes virus infections will be used to understand how pathogens interact with host cells. With this understanding we aim to identify which host cell signalling pathways play a critical role in limiting or faciliating pathogen persistence. After identifying the important cellular pathways we aim to target these host cell signalling components with clinical stage drugs to promote pathogen clearance.
Immunobilogy Of Human Herpesviruses: From Bench To Bedside
Funder
National Health and Medical Research Council
Funding Amount
$926,980.00
Summary
This Fellowship application is aiming to translate our newly emerging knowledge on immune regulation of human herpesviruses and associated diseases from bench to bedside. We are aiming develop new platform technologies which will allow us to test novel immunotherapeutic strategies to treat herpesvirus-associated diseases.
Towards HIV And Hepatitis C Elimination: Real-world Trials And Innovations In Disease Surveillance
Funder
National Health and Medical Research Council
Funding Amount
$640,210.00
Summary
Over the next five years I will undertake a program of research centred on developing and implementing strategies to help eliminate hepatitis C and HIV as major public health problems. In particular, I will use innovative monitoring systems and field trials to explore ways to diagnose and treat HIV and hepatitis C in vulnerable populations in a more timely way and study the influence this has on reducing the onward transmission of these infections to others.
Innovative Approaches To Reducing The Impact Of Blood Borne Viruses And Sexually Transmitted Infections On Young People.
Funder
National Health and Medical Research Council
Funding Amount
$246,859.00
Summary
Over the next 5 years I will undertake a program of research centred on reducing the impact of blood-borne viruses (BBVs) and sexually transmitted infections (STIs) in vulnerable populations, particularly young people. I will study how these infections are transmitted, associated risk behaviours including drug and alcohol use and sexual risk, and develop interventions to improve the detection and management of infected individuals.
I am a virologist working on hepatitis C virus with projects to investigate antiviral agents, vaccine technology, aspects of HCV immunity and treatment by immunotherapy.
Development Of New Therapies For Respiratory Diseases And Infection
Funder
National Health and Medical Research Council
Funding Amount
$847,490.00
Summary
Prof Hansbro’s group have developed world 1st experimental models of emphysema, severe asthma infection and lung cancer. He uses them to further our understanding of these untreatable diseases. This has led to the development of new potential therapeutic approaches. Now, in discovery programs he will expand studies of pathogenesis to identify new therapeutic targets these diseases. In development and translational programs he will progress new therapies towards clinical application.